Andros Pharmaceuticals Co Ltd

Andros Pharmaceuticals maintains a strong liquidity position with a current ratio of 13.97, indicating significant short-term asset coverage over liabilities, and holds TWD 53.76 million in cash and equivalents. The company's debt-to-equity ratio is 0.03, reflecting a conservative capital structure with minimal leverage. However, negative operating and free cash flows of TWD -45.45 million and TWD -48.00 million, respectively, suggest ongoing cash burn despite high liquidity. Profitability metrics are sharply negative, with a return on equity of -10.43% and return on assets of -9.62%, both well below industry norms for pharmaceutical firms. These figures indicate that the company is not generating returns sufficient to cover its cost of capital or asset base. Gross profit of TWD 1.80 million on TWD 5.55 million in revenue suggests margin compression, likely due to high R&D and manufacturing costs for its specialized formulations. The company's revenue is concentrated in two markets: Hong Kong and Taiwan, with no disclosed diversification into other regions. This geographic concentration increases exposure to local regulatory, economic, and competitive shifts. Product offerings are limited to niche generic drugs and high-end skincare, with no indication of blockbuster drug candidates or diversified therapeutic pipelines. Growth prospects are constrained by the company's current financial performance. With no disclosed revenue growth in the latest period and negative operating income of TWD -75.64 million, the company is not demonstrating scalable expansion. The outlook for the next fiscal year remains uncertain without significant operational or strategic changes. Risk factors include the company's reliance on a narrow product portfolio and geographic footprint, which could limit resilience to market disruptions. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses could necessitate future capital raises, potentially leading to dilution. Recent filings and transcripts do not disclose material events or strategic shifts. The company remains focused on its core product lines and regional markets, with no indication of new partnerships, product launches, or geographic expansion in the latest available data.